Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
2015/12/08 by J.L. Blok, K. Li, Carrie Brodmerkel +7 · 25 citations
Medicine · #Hidradenitis Suppurativa and Treatments #Autoimmune and Inflammatory Disorders #Acne and Rosacea Treatments and Effects
paper · doi:10.1111/bjd.14338
Abstract
BACKGROUND: Treatment of hidradenitis suppurativa (HS) is difficult and the search for effective therapies continues. OBJECTIVES: To evaluate the efficacy of ustekinumab and to discover a potential biomarker for HS. METHODS: Seventeen patients were included in this open-label study and treated with 45 or 90 mg ustekinumab at weeks 0, 4, 16 and 28. Proteomic technology and enzyme-linked assay analysis was applied to sera. RESULTS: Twelve patients completed the protocol. Moderate-to-marked improvement of the modified Sartorius score was achieved in 82% of patients at week 40 and the Hidradenitis Suppurativa Clinical Response 50 in 47%. With regard to the expression of 54 serum proteins, at baseline, a significant difference was observed between patients and healthy controls. Involved pathways were related to inflammation, immune cell signalling and tissue morphology/development. Good responders had milder disease and lower expression of leukotriene A4-hydrolase (LTA4H). Interleukin (IL)-2R, tumour necrosis factor-α, IL-17A and IL-17F were not elevated and did not change during treatment. CONCLUSIONS: The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive of the effectiveness of ustekinumab.
Cited by
- The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa. [europepmc]
- Immune response patterns in non-communicable inflammatory skin diseases. [europepmc]
- Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. [europepmc]
- Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. [europepmc]
- Hidradenitis Suppurativa: Causes, Features, and Current Treatments. [europepmc]
- Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. [europepmc]
- Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. [europepmc]
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. [europepmc]
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. [europepmc]
- The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin. [europepmc]
- An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis. [europepmc]
- Emerging Topical and Systemic JAK Inhibitors in Dermatology. [europepmc]
- Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. [europepmc]
- Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. [europepmc]
- Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. [europepmc]
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. [europepmc]
- The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. [europepmc]
- In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. [europepmc]
- Hidradenitis Suppurativa: Where We Are and Where We Are Going. [europepmc]
- Single-Cell RNA Sequencing Reveals Cellular and Transcriptional Changes Associated With M1 Macrophage Polarization in Hidradenitis Suppurativa. [europepmc]
- New perspectives on the treatment of hidradenitis suppurativa. [europepmc]
- New and Emerging Targeted Therapies for Hidradenitis Suppurativa. [europepmc]
- Racial disparities in dermatology. [europepmc]
- Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. [europepmc]
- Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis. [europepmc]
Related